The news from ESMO: The latest on anti-TIGIT data, a PD-(L)1 injection, and more
This is the online edition of ESMO in 30 Seconds, a pop-up newsletter from the European Society for Medical Oncology’s annual meeting in Barcelona, Spain. Sign up for the remaining editions here.
One of the big presentations of this year’s ESMO (at least in our view) comes tomorrow morning bright and early. David Spigel of Sarah Cannon Research Institute in Nashville will unveil results from the GALAXIES Lung-201 study of an anti-TIGIT therapy from iTeos Therapeutics and GSK in non-small cell lung cancer.
